The share price of companies is one of the most important factors that investors closely monitor in the constantly changing world of finance. One major player in the pharmaceutical industry, Gland Pharma, has drawn notice of its stock market performance. The purpose of this article is to examine the factors that impact the Gland Pharma Share Price.
About Gland Pharma
When it comes to developing injectable medications that are useful in a variety of therapeutic areas, Gland Pharma is the industry leader. The business is also in charge of developing an online storefront that enables customers to purchase its goods online with a prescription from a physician. As of right now, the company can easily produce 750 million units of its products at seven different locations in India. To supply completed formulations, the company’s four principal manufacturing facilities, in addition to the Active Pharmaceutical Ingredient (API) Facilities, each have 22 production lines. The products that the company produces are all supplied in liquid vials, ampoules, drops, and even bags. Syringes that have already been filled are also available.
The business is also working hard to develop a delivery system that can hold complex injectables like suspensions, peptides, and long-lasting injectables, as well as research manufacturing techniques. In addition, Gland Pharma Ltd is working to develop and research the synthesis of some of the most complicated molecules to produce their injectables. Last but not least, Gland Pharma Ltd is expanding its market for specialty pharmaceuticals in India and around the globe.
Products offered by Gland Pharma Ltd.
- Cardiac
- Respiratory
- Hormones
- Neuro / Cns
- Anti Materials
- Anti-Infectives
- Anti-Neoplastics
- Blood-Related
- Gynecological
- Gastro-Intestinal
- Pain / Analgesics
- Ophthal / Otologicals
- Vitamins / Minerals / Nutrients
Gland Pharma Ltd is Listed on 2 Exchanges
Other Listing Information
- 1978: PVN Raju founded Gland Pharma to produce and sell Heparin injections on the home market while also offering other pharmaceutical companies contract manufacturing services.
- 1994: It changes from being a private limited business to a public limited company.
- 1996: Becomes the first business in India to open a PFS facility.
- 2000: Signs its first contract with a regulated market for contract manufacturing.
- 2007: Introduce Ketorolac PFS to the US market.
- 2013: Introduced Tirofiban into European markets. The USFDA has given the Visakhapatnam Oncology Formulations Facility approval.
- 2016: The first approval for a Penems plant in Hyderabad and a Sterile Injectable plant in Pashamylaram, Hyderabad, was given by the USFDA in 2016. An API plant in VSEZ and another in Pharmacy, Visakhapatnam, received their first USFDA approvals.
- 2017: The company was majority-owned by Fosun Pharma.
- 2018: In the US, enoxaparin injection was approved for sale in 2018. The US has authorized the sale of its first ophthalmic product.
Gland Pharma Financials
| Indicator | Sep 2023 | Jun 2023 | Mar 2023 |
| Oper Rev Qtr Cr | 1,011 | 884 | 785 |
| Operating Expenses Qtr Cr | 664 | 625 | 616 |
| Operating Profit Qtr Cr | 347 | 259 | 169 |
| Depreciation Qtr Cr | 40 | 39 | 38 |
| Interest Qtr Cr | 1 | 2 | 2 |
| Tax Qtr Cr | 90 | 66 | 33 |
| Net Profit Qtr Cr | 258 | 188 | 79 |
Gland Pharma Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
| Day | 153,213 | 5,782,259 | 37.74 |
| Week | 326,583 | 14,359,855 | 43.97 |
| 1 Month | 240,349 | 13,358,579 | 55.58 |
| 6 Month | 380,268 | 18,020,897 | 47.39 |
NSE-Medical-Generic Drugs
| Market Cap | 33,227 |
| Sales | 3,606 |
| Shares in Float | 6.92 |
| No of funds | 139 |
| Yield |
| Book Value | 4.16 |
| U/D Vol ratio | 2 |
| LTDebt / Equity | |
| Alpha | 0.18 |
| Beta | 0.4 |
Gland Pharma
| Owner Name | Dec-23 | Sep-23 | Jun-23 | Mar-23 |
| Promoters | 57.86% | 57.86% | 57.86% | 57.86% |
| Mutual Funds | 21.34% | 19.79% | 20.48% | 20.25% |
| Insurance Companies | 1.8% | 1.79% | 1.8% | 2.02% |
| Foreign Portfolio Investors | 4.05% | 4.91% | 2.8% | 4.33% |
| Financial Institutions/ Banks | 0.01% | |||
| Individual Investors | 3.79% | 4.52% | 5.61% | 4.27% |
| Others | 11.16% | 11.12% | 11.45% | 11.27% |
Gland Pharma Management
| Name | Designation |
| Mr. Yiu Kwan Stanley Lau | Chairman & Ind.Director |
| Mr. Srinivas Sadu | Managing Director & CEO |
| Mr. Qiyu Chen | Non-Executive Director |
| Mr. Yao Fang | Non-Executive Director |
| Dr. Jia Ai (Allen) Zhang | Non-Executive Director |
| Mr. Udo Johannes Vetter | Independent Director |
| Mr. Satyanarayana Murthy Chavali | Independent Director |
| Mr. Essaji Goolam Vahanvati | Independent Director |
Global Out-Licensing
- Regulated Markets: We collaborate with multiple pharmaceutical companies through cost- and profit-sharing arrangements. With our marketing partners, we enter into long-term development, manufacturing, supply, and medicine licensing agreements.
- Early Stage Licensing: We assess your range of generic product needs and offer comprehensive, value-added solutions that cover everything from the creation of formulations and APIs to the compilation and submission of dossiers. We also provide partners with a similar product interest with access to our pipeline of conceptualized products
- Late Stage Licensing: We provide our products in a range of development stages, from formulations created on a lab scale to formulations that are prepared for scaling up. In addition, we give partners access to developed products that are prepared for dossier submission and products that have already been filed and are pending approval, thus offering a dynamic go-to-market strategy. With these pharmaceutical companies, we enter into loan and license agreements for the manufacturing of medicines, and we are paid a fixed amount for manufacturing and packaging for each unit produced.
- Semi-Regulated Markets: Partners can launch our ready-to-register portfolio in their respective markets. With the help of concerned local majors, we already have a significant presence in these markets thanks to ongoing product registrations, upcoming ones, and pending dossiers. More than 60 nations in Latin America, the Middle East, North Africa, Asia Pacific, Africa, the Common Wealth of Independent States, and South Africa are receiving our products.
FAQ of Gland Pharma Share Price
Q1. What is Gland Pharma’s P/E ratio?
Gland Pharma’s P/E ratio is 47.2. on February 12, 2024
Q2. What is Gland Pharma’s PB ratio?
As of February 12, 2024, Gland Pharma’s PB ratio is 4.2.
Q3. What is Gland Pharma’s share price?
The share price of Gland Pharma as of February 12, 2024, is ₹2,003.
Q4. What is Gland Pharma’s market capitalization?
Gland Pharma’s market capitalization is ₹32998 Cr. on February 12, 2024
Q5. How can I purchase Gland Pharma Ltd. shares online?
The company’s shares can be purchased offline or online by confirming the KYC documents and creating a Demat account with the Broker website.
Conclusion
The dynamics of Gland Pharma share price are influenced by various factors. This article explores the historical perspective, market trends, regulatory environment, global economic factors, financial performance, competitive landscape, and investor sentiment surrounding Gland Pharma’s stock. Consistent tracking of these facets is deemed imperative by investors, analysts, and enthusiasts to fully comprehend the complexities of the pharmaceutical industry and enable wise investment selections.
Leave a Comment